

WHAT IS A FAIR PRICE FOR CANCER MEDICINES?

Launch of ECL's definition of a fair price and reflections on a fair pricing policy
2 September 2020, 09:30-11:00 CEST, ZOOM Webinar

09:30-09:35	Welcome by Ward Rommel, Chair, ECL Access to Medicines Task Force
09:35-09:45	Affordability & Fair Pricing in the EU Pharmaceutical Strategy Sylvain Giraud, European Commission, DG SANTE
09:45-10:00	Fair pricing policy & Introduction of ECL's Fair Price Definition Lone Bilde, Danish Cancer Society
10:00-10:20	Reflection of Stakeholders on ECL's Fair Price Definition <ul style="list-style-type: none"> • Simone Boselli, EURORDIS-Rare Diseases Europe • Anne Hendrickx, Solidaris (Belgian Mutual Fund), Member of the International Association of Mutual Benefit Societies (AIM)'s Pharmaceutical Working Group • Allison Colbert, World Health Organization Discussion with webinar participants
10:20-10:35	How do we get there? Recommendations for Decision Makers & Pharmaceutical Industry Anna Prokupkova, Association of European Cancer Leagues (ECL)
10:35-10:55	Reactions to ECL's Recommendations <ul style="list-style-type: none"> • Sylvain Giraud, DG SANTE, European Commission • Véronique Trillet-Lenoir, MEP (RE, France) • René Imhof, Head of Global Pricing, Roche Discussion with webinar participants
10:55-11:00	Closing Remarks by Ward Rommel, ECL

